Difference between revisions of "Gilteritinib (Xospata)"

Revision as of 18:49, 29 November 2018

Tyrosine kinase inhibitor of FLT3, AXL, and ALK

11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

@@ Line 2: / Line 2: @@
 Tyrosine kinase inhibitor of FLT3, AXL, and ALK
-==Preliminary data==
+==Diseases for which it is used==
-===[[Acute myeloid leukemia]]===
+*[[Acute_myeloid_leukemia,_FLT3-positive|FLT3+ AML]]
-# Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 Aug;18(8):1061-1075. Epub 2017 Jun 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30416-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28645776 PubMed]
+==History of changes in FDA indication==
+*11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory [[Acute_myeloid_leukemia,_FLT3-positive|acute myeloid leukemia (AML) with a FLT3 mutation]] as detected by an FDA-approved test.
+==Also known as==
+*'''Code name:''' ASP2215
+*'''Brand name:''' Xospata
 [[Category:Drugs]]
-[[Category:Chemotherapy]]
 [[Category:Oral medications]]
@@ Line 15: / Line 20: @@
 [[Category:FLT3 inhibitors]]
-[[Category:Investigational]]
+[[Category:FDA approved in 2018]]